Literature DB >> 11309708

Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases.

W C Liles1.   

Abstract

Neutrophils, monocytes, and tissue-based macrophages are major cellular components of the innate immune system, which represents the initial line of host defense against invading pathogens. Four cytokines-granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), and interferon-gamma (IFN-gamma)--have received increasing attention as potential adjunctive immunomodulatory agents for treatment of infectious diseases. Studies conducted in vitro and in vivo have shown that G-CSF, GM-CSF, and IFN-gamma can augment the functional antimicrobial activities of neutrophils. Similarly, GM-CSF, M-CSF, and IFN-gamma up-regulate multiple antimicrobial mechanisms in monocytes and macrophages. Studies conducted in animal models have shown the potential use of each of these cytokines for the treatment of infections caused by a variety of bacterial, fungal, and parasitic diseases. Because clinical experience with these immunomodulatory cytokines is relatively limited and currently investigational, controlled clinical trials will be necessary to define specific indications for the administration of these cytokines in therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309708     DOI: 10.1053/srin.2001.22724

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  10 in total

1.  EGCG induces G-CSF expression and neutrophilia in experimental sepsis.

Authors:  Wei Li; Andrew H Wu; Shu Zhu; Jianhua Li; Rong Wu; John D'Angelo; Haichao Wang
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

2.  Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice.

Authors:  Yue Si; Samantha Ciccone; Feng-Chun Yang; Jin Yuan; Daisy Zeng; Shi Chen; Henri J van de Vrugt; John Critser; Fre Arwert; Laura S Haneline; D Wade Clapp
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

3.  Calcium regulation of GM-CSF by calmodulin-dependent kinase II phosphorylation of Ets1.

Authors:  Hebin Liu; Thomas Grundström
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

Review 4.  Targeting HMGB1 in the treatment of sepsis.

Authors:  Haichao Wang; Mary F Ward; Andrew E Sama
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

5.  Glycine induces enhancement of bactericidal activity of neutrophils.

Authors:  Shin-Hae Kang; Hwa-Yong Ham; Chang-Won Hong; Dong-Keun Song
Journal:  Korean J Physiol Pharmacol       Date:  2022-07-01       Impact factor: 1.718

6.  Female scent signals enhance the resistance of male mice to influenza.

Authors:  Ekaterina A Litvinova; Elena P Goncharova; Alla M Zaydman; Marina A Zenkova; Mikhail P Moshkin
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

Review 7.  Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.

Authors:  Haichao Wang; Mary F Ward; Andrew E Sama
Journal:  Shock       Date:  2009-10       Impact factor: 3.454

Review 8.  Endogenous Regulation and Pharmacological Modulation of Sepsis-Induced HMGB1 Release and Action: An Updated Review.

Authors:  Cassie Shu Zhu; Wei Wang; Xiaoling Qiang; Weiqiang Chen; Xiqian Lan; Jianhua Li; Haichao Wang
Journal:  Cells       Date:  2021-08-27       Impact factor: 6.600

Review 9.  Therapeutic potential of HMGB1-targeting agents in sepsis.

Authors:  Haichao Wang; Shu Zhu; Rongrong Zhou; Wei Li; Andrew E Sama
Journal:  Expert Rev Mol Med       Date:  2008-11-04       Impact factor: 5.600

10.  Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages.

Authors:  D Shane O'Mahony; Uyenvy Pham; Ramesh Iyer; Thomas R Hawn; W Conrad Liles
Journal:  Int J Med Sci       Date:  2008-01-04       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.